I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Concurrent celecoxib with 5-fluorouracil/epirubicin/cycloph..:
Chow, Louis W. C
;
Tung, Stewart Y
;
Ng, Ting-Ying
...
Expert Opinion on Investigational Drugs, Vol.22 No.3, pp.299-307. , 2021
Link:
https://hdl.handle.net/10371/177237
RT Journal T1
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II-III invasive breast cancer: the OOTR-N001 study
UL https://suche.suub.uni-bremen.de/peid=base-ftseoulnuniv:oai:s-space.snu.ac.kr:10371_177237&Exemplar=1&LAN=DE A1 Chow, Louis W. C A1 Tung, Stewart Y A1 Ng, Ting-Ying A1 Im, Seock-Ah A1 Lee, Min-Hyuk A1 Yip, Adrian Y. S A1 Toi, Masakazu A1 Glueck, Stefan PB Ashley Publications Ltd. YR 2021 K1 SURGICAL ADJUVANT BREAST K1 PHASE-II K1 NEOADJUVANT CHEMOTHERAPY K1 PREOPERATIVE DOXORUBICIN K1 COX-2 INHIBITORS K1 CYCLOPHOSPHAMIDE K1 TRIAL K1 FEC K1 CAPECITABINE K1 PREDICTS K1 breast cancer K1 celecoxib K1 cyclooxygenase-2 JF Expert Opinion on Investigational Drugs, Vol.22 No.3, pp.299-307 LK http://dx.doi.org/https://hdl.handle.net/10371/177237 DO https://hdl.handle.net/10371/177237 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)